Anchiano Therapeutics Ltd. is expected to issue 2.4 million shares at $14.55 each Tuesday on the Nasdaq.The company is developing a single biologic candidate to treat bladder and other cancers. Anchiano has had promising trial results, strong existing investor support of the IPO, and a low IPO valuation, but the early stage of its development may mean the IPO is more appropriate for high risk, long-term life science investors.

In last year's volatile market, healthcare remained a strong investment for those seeking growth.As we start 2019, healthcare remains a favorite sector of Wall Street, according to a report in Reuters.  Supporters say the healthcare sector has reasonable valuations, strong balance sheets and dividend payments. For 2019, healthcare companies in the S&P 500 are expected to increase earnings by 7.5 percent, ahead of the 6.3 percent growth estimated for S&P 500 companies overall, according to IBES data from Refinitiv.

A new study by the Centers for Medicare and Medicaid Services says Americans paid $3.5 trillion on healthcare in 2017, which amounts to $10,739 per person." Private health insurance had the highest spending with an increase of 4.2 percent to $1.2 trillion, in 2017.

Shares of Johnson & Johnson JNJ, +0.03% fell 3.3% in afternoon trade, enough to pace declines among its health care peers and among the Dow Jones Industrial Average's DJIA, +1.46% components, after reports that an appeals court ruled that J&J can't block sales of generic Zytiga while the company appeals the overturning of a Zytiga patent.  READ MORE...

Principia Biopharma continued its impressive progress with its recent initial public offering on September 14, 2018.Principia Biopharma (Nasdaq: PRNB) has developed three drug candidates in immunology, central nervous system disorders, and oncology. The company is utilizing 'Tailored Covalency,' its proprietary drug discovery platform, to discover new drugs that combine the dosing ability of an oral small molecule drug with the specificity of an antibody. Standard small molecule drugs have a short duration of time that the drug binds to its target, called residence time, that require dosing regimens to maintain target concentration levels in the blood to get the desired result. Principia has designed its drugs to remain bound to the target, and clear the body rapidly, to optimize residence time.